Latest Content

A healthy New Jersey man succumbed to the allergy after eating red meat. A blood sample collected post-mortem found that he had been sensitized to the sugar, alpha-gal, found in mammals. The blood sample indicated the man had an extreme reaction, in line with what is seen in fatal anaphylaxis.

ByHeart Whole Nutrition Infant Formula is the product involved in the recall. Fifteen infants have been hospitalized in 12 states prompting a federal investigation. Clinicians are urged to treat on suspicion and report all cases.

Gilead reports its investigational single tablet of bictegravir and lenacapavir was efficacious in people with HIV who are virologically suppressed and who switched from taking multitablet regimens. The company says its phase 3 study results will form the basis for its future regulatory submissions.

During National C difficile Awareness Month, the Peggy Lillis Foundation is working toward greater awareness about prescribing practices as well as cleaning methods that can prevent infections.

The tool's developer, LIV Process, says it has created a water-based reagent that illuminates Clostridioides difficile on surfaces so teams can verify cleaning in real time.

Rachel Britt, PharmD, BCIDP, provides insights on an evolving understanding of the long-time antibiotic’s limitations for these infections and provides guidance on other agents and the role of diagnostics in finding the best agents for patients.

Immunocore’s first-in-human study of its bispecific, IMC-I109V, demonstrated early antiviral activity and a favorable safety profile, supporting continued development of the TCR bispecific candidate as a potential functional cure for chronic hepatitis B.

In Vir Biotechnology’s phase 2 Solstice study, 66% of participants with chronic hepatitis delta (CHD) receiving a monthly dose of combination tobevibart and elebsiran achieved undetectable hepatitis delta virus (HDV) RNA at Week 48.

Seven months of clinical data corroborated emergency authorization of 2024-2025 mRNA COVID-19 vaccines for circulating JN.1 subvariants.

This week, read about the FDA's approval of IV antibiotic, Contepo, for complicated urinary tract infections, penicillin‑binding proteins, post-exposure doxycycline for Lyme disease prevention in young children, and more.

PBPs are more than static β lactam targets. Host conditions rewire PBP activity and peptidoglycan architecture, shaping tolerance, resistance, and how we design salvage regimens.

Despite a 2018 American Academy of Pediatrics clinical update that recommends use of postexposure prophylaxis for prevention of the tick-borne disease in children younger than 8 years, Wesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA, points out many clinicians are unaware of this. He also discusses its efficacy at preventing the disease in this patient population.

Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late 2026.